Abstract CT022: First data disclosure of the Phase I trial of the first in class combination of WEE1 inhibitor zedoresertib with PKMYT1 inhibitor lunresertib in patients with advanced solid tumors harboring CCNE1, FBXW7, or PPP2R1A genomic alterations
Timothy A. Yap(The University of Texas MD Anderson Cancer Center), Alison M. Schram(Memorial Sloan Kettering Cancer Center), Martin Højgaard(Rigshospitalet), Linda Duska(University of Virginia Health System), Christophe Mas(Debiopharm (Switzerland)), Stéphanie Lheureux(Princess Margaret Cancer Centre), Noemie Luong(Debiopharm (Switzerland)), Ryan H. Moy(Columbia University Irving Medical Center), Vito Dozio(Swiss Centre for Applied Human Toxicology), Gerardo Colón‐Otero(Jacksonville College), Benedito A. Carneiro(Brown University), Esteban Rodrigo Imedio(Debiopharm (Switzerland)), Siddhartha Yadav(Cornell University), Jonathan Wessen(AstraZeneca (United Kingdom)), Mia Weiss(University of Washington), Patricia LoRusso, Ignacio Garrido-Laguna(Huntsman Cancer Institute), Cara Mathews(Women & Infants Hospital of Rhode Island), Luke Piggott(Debiopharm (Switzerland)), Joan Tymon-Rosario(Northwell Health), Elisabeth K. Lee(Dana-Farber Cancer Institute), Elisa Fontana(Sarah Cannon Research Institute), Rahul Aggarwal(UCSF Helen Diller Family Comprehensive Cancer Center), Nehal J. Lakhani(South Texas Accelerated Research Therapeutics)
Cited by 0
Related Papers
A Population-Based Study of Genes Previously Implicated in Breast Cancer
|New England Journal of Medicine|2021|862
Efficacy of Selpercatinib in <i>RET</i> -Altered Thyroid Cancers
|New England Journal of Medicine|2020|766
First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers
|Journal of Clinical Oncology|2019|590
Melanomas require HEDGEHOG-GLI signaling regulated by interactions between GLI1 and the RAS-MEK/AKT pathways
|Proceedings of the National Academy of Sciences|2007|531